Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
Kelowna, British Columbia– October 8, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this…
Peer Reviewed Clinical Journal Publishes Lexaria Bioscience’s Human CBD Study Results
Kelowna, British Columbia– September 17, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that…
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions
Kelowna, British Columbia– August 27, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that…
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil
Kelowna, British Columbia – August 22, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce…
Lexaria Bioscience Announces it has Received Four New Patents
Kelowna, British Columbia– August 15, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that…
Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors
Kelowna, British Columbia– August 14, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the…
Lexaria Bioscience Receives Cannabis R&D License from Health Canada
Kelowna, British Columbia– August 13, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that…
Lexaria Bioscience Completes Initial Project with Canada’s National Research Council
No chemical modification or degradation of Active Pharmaceutical Ingredients evidenced using DehydraTECH after acidic pH stability testing Strategically significant absence of covalent-bonded New Molecular Entity creation using DehydraTECH Kelowna, British…
Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services
Kelowna, BC – August 2, 2019 – Lexaria Bioscience Corp. (CNSX: LXX) (OTCQB: LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor…
Lexaria Bioscience Summarizes its Eleven Technology Licenses
Kelowna, British Columbia – July 30, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology…